Perry Dimas
42 episodes listed below
Precision medicine, tested against reality.
The Promise of Personalized Medicine sits at the practical edge of precision care: tests, coverage, guidelines, privacy, and adoption. Its conversations move between medical directors, lab professionals, patients, and industry voices trying to make targeted treatment usable in real health systems.
PRESS PLAY
The Promise of Personalized Medicine is built around a blunt premise: precision care depends on diagnostic tests that can survive the real world of coverage, adoption, regulation, and clinical workflow. It is not a general wellness show. Its center is the professional ecosystem around novel diagnostics, especially the lab professionals and medical directors trying to move useful tests from evidence into everyday care. Episodes often start with definitions because the term personalized medicine means different things to different parts of health care. That becomes part of the point. A pathologist's view emphasizes matching treatment to a patient's disease while also avoiding therapies that are unlikely to help. A patient perspective adds another layer. Christine Von Raesfeld describes the difficulty of getting usable genomic data, finding doctors willing to look beyond standard care, and balancing privacy with the collective value of research participation. Those conversations make the show more than a policy roundtable. They show how data ownership, security, privacy, and trust can either accelerate or block precision medicine. Coverage is another recurring pressure point. The series returns to health plans, payer needs, guidelines, biomarker laws, and the different ways industry responds when government pushes diagnostic coverage forward. FDA involvement in laboratory medicine appears as a long-running unresolved issue rather than a sudden headline. The show also makes room for year-end reflection, using the format to compare innovation, regulation, health economics, and clinical expectations across the field. Its pacing is conversational but professional. The vocabulary assumes comfort with biomarkers, payers, indications, laboratory medicine, and diagnostic approval pathways. Still, the best episodes keep the stakes visible. A test is not only a scientific object; it is a route to the right treatment, a way to avoid harm, and a challenge to the systems that decide what patients can access. For PlayNext listeners interested in medicine's operational layer, it offers a clear view of personalized care being argued, defined, and negotiated in practice.
Made for: For lab professionals, medical directors, health plan observers, diagnostic innovators, and clinically curious listeners who want the practical path from test development to covered care.
What sets it apart: The show keeps personalized medicine grounded in diagnostic adoption rather than broad futurism. It pairs payer and regulatory discussion with patient access, data ownership, and clinical decision-making.
There is no personalized medicine without a diagnostic test to help in the process. The Promise of Personalized Medicine is a podcast that explores the process of creating more personalized medicine and the Medical Directors who ensure that the right care is being delivered to us all. Season 1 will focus on understanding best practices by using the Blueprint of Success format as a template for labs to use when trying to get their novel diagnostic test approved by health plans. This is The Promise of Personalized Medicine.
Short reviews from the PlayNext desk, based on the episodes we processed.
A patient-centered argument for data access, privacy, and tests that can return value to care.
Christine steers The Promise of Personalized Medicine into patient territory, and the host notes that this is the first direct patient conversation after earlier episodes centered on payer perspective.
Morning medical evidence, compressed for practice.
Medical research, translated through patient experience.
Host Perry Demas and physician Michelle discuss why genetic tests like pharmacogenomics and cardiac markers such as lipoprotein(a) and coronary calcium scoring struggle to win coverage.
Christine Von Raesfeld says she has "three joint replacements" and "toxic encephalopathy" from standard care.
Dr.
Tyler O'Malley and Perry discuss how personalized medicine can replace symptom-based classification with patient-specific information for diagnosis and treatment.
Perry Demas and physician-radiologist Mark Hyatt compare personalized medicine with standard-of-care treatment, asking whether population guidelines can accommodate individual patients.
Tom explains to Perry why personalized medicine companies need reimbursement to cover testing costs, fund research and development, and support long-term operations.
The Promise of Personalized Medicine examines precision medicine as an ecosystem built around using the right testing for the right patient at the right time.